Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia,
Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Neuroendocrinology. 2023;113(3):281-288. doi: 10.1159/000526848. Epub 2022 Sep 1.
Hormonal crises are a rare but increasingly recognized phenomenon following peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms (NENs). Due to the paucity of published studies, approaches to the identification, prevention, and management of risk factors are inconsistent between different institutions. This consensus statement aimed to provide guidance for NEN patients undergoing PRRT. Our statement has been created on the basis of clinical demand and concerns regarding the precipitation of hormonal crises. A formal literature review was conducted to identify available studies. A total of 19 Australian and New Zealand experts in the fields of medical oncology, nuclear medicine, anaesthetics, and endocrinology collaborated on this consensus statement. The main focus is on carcinoid crises. Other hormonal crises seen in patients with functional pancreatic NENs are addressed briefly. These recommendations are relevant to PRRT centres internationally and should be tailored to local experience and available resources.
激素危象是一种罕见但日益被认识到的现象，在神经内分泌肿瘤（NENs）患者接受肽受体放射性核素治疗（PRRT）后会出现。由于发表的研究较少，不同机构之间在识别、预防和管理危险因素的方法上存在不一致。本共识声明旨在为接受 PRRT 的 NEN 患者提供指导。我们的声明是基于临床需求和对激素危象发生的关注而制定的。进行了一次正式的文献回顾，以确定可用的研究。来自澳大利亚和新西兰的 19 名医学肿瘤学、核医学、麻醉学和内分泌学领域的专家合作制定了这项共识声明。主要重点是类癌危象。简要介绍了功能性胰腺 NEN 患者中出现的其他激素危象。这些建议与国际 PRRT 中心相关，应根据当地经验和可用资源进行调整。
